Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis: symptomatic treatment

A J Thompson1

  • 1Department of Clinical Neurology, National Hospital for Neurology and Neurosurgery, London, UK.

Journal of Neurology
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B.

The Journal of infectious diseases·2025
Same author

Balancing Efficiency and Accuracy in Hepatitis C Rapid Antibody Testing: Insights From a Cluster Randomised Crossover Trial.

Journal of viral hepatitis·2025
Same author

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B.

Alimentary pharmacology & therapeutics·2025
Same author

New insights into the effects of ethylene on ABA catabolism, sweetening and dormancy in stored potato tubers.

Postharvest biology and technology·2021
Same author

Direct Measurement of Single-Molecule Ligand-Receptor Interactions.

The journal of physical chemistry. B·2020
Same author

Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2019
Same journal

The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.

Journal of neurology·2026
Same journal

Brain-first versus body-first Parkinson's disease: Differential findings on pupillary, brainstem and vagus sonography.

Journal of neurology·2026
Same journal

Spontaneous intracranial hypotension due to pelvic cerebrospinal fluid leak.

Journal of neurology·2026
Same journal

Morbidity and medication use preceding a diagnosis of late-onset Alzheimer's disease: a Danish nationwide study.

Journal of neurology·2026
Same journal

Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.

Journal of neurology·2026
Same journal

Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome.

Journal of neurology·2026
See all related articles

New multiple sclerosis therapies show limited symptom improvement. Focus on multidisciplinary symptomatic management, including physical, pharmacological, and surgical approaches, offers better quality of life for patients with multiple sclerosis.

Area of Science:

  • Neurology
  • Immunology
  • Rehabilitation Medicine

Background:

  • Emerging therapeutic agents for multiple sclerosis (MS) inflammation show limited clinical impact on patient symptoms and disability.
  • Current management strategies for MS primarily rely on symptomatic treatments.

Purpose of the Study:

  • To review symptomatic treatment approaches for the diverse challenges faced by multiple sclerosis patients.
  • To emphasize the importance of a multidisciplinary strategy for optimizing outcomes in multiple sclerosis management.

Main Methods:

  • Literature review of physical, pharmacological, and surgical management advancements for multiple sclerosis.
  • Analysis of symptomatic treatment options for a wide range of MS-related difficulties.
  • Integration of findings within a multidisciplinary care framework.

Related Experiment Videos

Main Results:

  • New anti-inflammatory agents have not significantly improved multiple sclerosis symptoms, disability, or handicap.
  • Physical, pharmacological, and surgical interventions offer substantial opportunities for enhancing patient quality of life in the medium term.
  • Symptomatic management is crucial for addressing the multifaceted issues in multiple sclerosis.

Conclusions:

  • A multidisciplinary approach integrating symptomatic treatments is essential for improving the quality of life for individuals with multiple sclerosis.
  • Clinical application of advances in physical, pharmacological, and surgical management holds greater promise than novel anti-inflammatory agents for immediate patient benefit.
  • Optimizing outcomes in multiple sclerosis requires comprehensive management addressing the whole spectrum of patient difficulties.